Guarana (Paullinia cupana) Improves Anorexia in Patients with Advanced Cancer

REFERENCES

• Andersen T, Fogh J. Weight loss and delayed gastric emptying following a South American herbal preparation in overweight patients. J Hum Nutr Diet. 2001;14(3):243–250.
   PubMed Web of Science ®Google Scholar
• Baracos VE. Clinical trials of cancer cachexia therapy, now and hereafter. J Clin Oncol. 2013;31(10):1257–1258.
   PubMed Web of Science ®Google Scholar
• Cardona D. Tratamiento farmacologico de la anorexia–caquexia cancerosa [Pharmacological treatment of anorexia–cachexia in cancer]. Nutr Hosp. 2006;21:17–26.
   PubMed Web of Science ®Google Scholar
• Cleeland CS, Mendoza TR, Wang XS, et al. Assessing symptom distress in cancer patients: the M. D. Anderson Symptom Inventory. Cancer. 2000;89:1634–1646.
   PubMed Web of Science ®Google Scholar
• da Costa Miranda V, Trufelli DC, Santos J, et al. Effectiveness of guarana (Paullinia cupana) for postradiation fatigue and depression: results of a pilot double-blind randomized study. J Altern Complement Med. 2009;15:431–433.
   PubMed Web of Science ®Google Scholar
• Del Fabbro E, Dev R, Hui D et al. Effects of melatonin on appetite and other symptoms in patients with advanced cancer and cachexia: a double-blind placebo-controlled trial. J Clin Oncol. 2013;31:1271–1276.
   PubMed Web of Science ®Google Scholar
• Fukumasu H, Avanzo JL, Nagamine MK, et al. Paullinia cupana Mart var. sorbilis, guaraná, reduces cell proliferation and increases apoptosis of B16/F10 melanoma lung metástases in mice. Braz J Med Biol Res. 2008;41:305–310.
   PubMed Web of Science ®Google Scholar
• Gabrilove JL, Perez EA, Tomita DK, et al. Assessing symptom burden using the M. D. Anderson symptom inventory in patients with chemotherapy-induced anemia: results of a multicenter, open-label study (SURPASS) of patients treated with darbepoetin-α at a dose of 200 microg every 2 weeks. Cancer. 2007;110:1629–1640.
   PubMed Web of Science ®Google Scholar
• Harrold JA, Hughes GM, O'Shiel K, Quinn E, Boyland EJ, Williams NJ, Halford JC. Acute effects of a herb extract formulation and inulin fibre on appetite, energy intake and food choice. Appetite. 2013;62:84–90.
   PubMed Web of Science ®Google Scholar
• Ishikawa NM, Thuler LCS, Giglio AG, et al. Validation of the Portuguese version of Functional Assessment of Cancer Therapy–Fatigue (FACT-F) in Brazilian cancer patients. Support Care Cancer. 2010;18:481–490.
   PubMed Web of Science ®Google Scholar
• Laird BJ, McMillan DC, Fayers P, et al. The systemic inflammatory response and its relationship to pain and other symptoms in advanced cancer. Oncologist. 2013;18:1050–1055.
   PubMed Web of Science ®Google Scholar
• Luckett T, King MT, Butow PN, et al. Choosing between the EORTC QLQ-C30 and FACT-G for measuring health-related quality of life in cancer clinical research: issues, evidence and recommendations. Ann Oncol. 2011;22:2179–2190.
   PubMed Web of Science ®Google Scholar
• Mantovani G, Mededdu C, Macciò A. Drugs in development for treatment of patients with cancer-related anorexia and cachexia syndrome. Drug Des Devel Ther. 2013;7:645–656.
   PubMed Web of Science ®Google Scholar
• Madeddu C, Dessi M, Panzone F, et al. Randomized phase III clinical trial of a combined treatment with carnitine + celecoxib ± megestrol acetate for patients with cancer-related anorexia/cachexia syndrome. Clin Nutr. 2012;31:176–182.
   PubMed Web of Science ®Google Scholar
• Mantovani G, Macciò A, Madeddu C, et al. Randomized phase iii clinical trial of five different arms of treatment in 332 patients with cancer cachexia. Oncologist. 2010;15:200–211.
   PubMed Web of Science ®Google Scholar
• Mantovani G, Maccio A, Madeddu C, et al. A phase II study with antioxidants, both in the diet and supplemented, pharmaconutritional support, progestagen, and anti-cyclooxygenase-2 showing efficacy and safety in patients with cancer-related anorexia/cachexia and oxidative stress. Cancer Epidemiol Biomarkers Prev. 2006;15:1030–1034.
   PubMed Web of Science ®Google Scholar
• Mantovani G, Madeddu C, Maccio A, et al. Cancer-related anorexia/cachexia syndrome and oxidative stress: an innovative approach beyond current treatment. Cancer Epidemiol Biomarkers Prev. 2004;13:1651–1659.
   PubMed Web of Science ®Google Scholar
• Marcon R, Del Giglio A, Pianowski LF, Calixto JB. Analysis of the role of Paulinia cupana (Guaraná) in blood IL-1b and brain IL-6 levels as well as brain IL-6 and TNF-a mRNA expression in mice. J Clin Oncol. 2011;29:2011[suppl; abstract e21002].
   PubMed Web of Science ®Google Scholar
• Pittler MH, Schmidt K, Ernst E. Adverse events of herbal food supplements for body weight reduction: systematic review. Obes Rev. 2005;6(2):93–111.
   PubMed Web of Science ®Google Scholar
• Campos MPO, Riechelmann R, Martins LC, et al. Guarana (Paullinia cupana) improves fatigue in breast cancer patients undergoing systemic chemotherapy. J Altern Complement Med. 2011;17:505–512.
   PubMed Web of Science ®Google Scholar
• Rodrigues M, Alves G, Lourenço N, Falcão A. Herb–drug interaction of Paullinia cupana (Guarana) seed extract on the pharmacokinetics of amiodarone in rats. Evid Based Complement Alternat Med. 2012;428560
   PubMedGoogle Scholar
• Silva MPN. Anorexia-cachexia syndrome in cancer patients. Rev Bras de Cancerologia. 2006;52:59–77.
   Google Scholar
• Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials. 1989;10:1–10.
   PubMedGoogle Scholar
• Sorensen JB, Klee M, Palshof T, Hansen HH. Performance status assessment in cancer patients. An inter-observer variability study. Br J Cancer. 1993;67:773–775.
   PubMed Web of Science ®Google Scholar
• Suzuki H, Asakawa A, Amitani H, et al. Cancer cachexia—pathophysiology and management. J Gastroenterol. 2013;48:574–594.
   PubMed Web of Science ®Google Scholar
• Tuca A, Jimenez-Fonseca P, Gascón P. Clinical evaluation and optimal management of cancer cachexia. Crit Rev Oncol Hematol. 2013;88:625–636.
   PubMed Web of Science ®Google Scholar
• U.S. Department of Health and Human Services, National Institutes of Health, National Cancer Institute. Common terminology criteria for adverse events (CTCAE) version 4.0. EORTC. 2010; http://www.eortc.be/services/doc/ctc/CTCAE_4.03_2010-06-14_QuickReference_5×7.pdf. Retrieved 6 December, 2013.
   Google Scholar
• Wen HS, Li X, Cao YZ, et al. Clinical studies on the treatment of cancer cachexia with megestrol acetate plus thalidomide. Chemotherapy. 2012;58:461–467.
   PubMed Web of Science ®Google Scholar
• Wheelwright S, Darlington AS, Hopkinson JB, et al. A systematic review of health-related quality of life instruments in patients with cancer cachexia. Support Care Cancer. 2013;21:2625–2636.
   PubMed Web of Science ®Google Scholar
• Yennurajalingam S, Willey JS, Palmer JL, et al. The role of thalidomide and placebo for the treatment of cancer-related anorexia-cachexia symptoms: results of a double-blind placebo-controlled randomized study. J Palliat Med. 2012;15:1059–1064.
   PubMed Web of Science ®Google Scholar
• Younes RN, Noguchi Y. Pathophysiology of cancer cachexia. Rev Hosp Clín Fac Med Sao Paulo. 2000;55:181–193.
   PubMedGoogle Scholar
• Zubrod CG, Scheiderman M, Frei E, Brindley C, et al. Cancer—appraisal of methods for the study of chemotherapy of cancer in man: thiophosphamide. J Chronic Dis. 1960;11:7–33.
   Google Scholar